Article Text

Download PDFPDF
Managing tricuspid valve regurgitation: a long and winding road
  1. Samuel Bernard,
  2. Judy Hung
  1. Medicine/Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA
  1. Correspondence to Dr Judy Hung, Medicine/Cardiology, Massachusetts General Hospital, Boston, MA 02114, USA; jhung{at}partners.org

Statistics from Altmetric.com

Moderate to severe tricuspid regurgitation (TR) is associated with increased morbidity and mortality, both in isolation and in combination with left-sided heart disease.1 2 Of the 1.6 million patients in the USA with moderate to severe TR, the vast majority have functional TR in the setting of left-sided heart disease and associated pulmonary hypertension.

Clinicians have long struggled with how to optimally manage these patients. Diuretics are a mainstay of medical therapy, and for those with concomitant heart failure with a reduced ejection fraction (HFrEF), optimal medical therapy (OMT) is recommended. In general, however, medical therapy will not reverse progressive right ventricular dysfunction with significant TR and has not been associated with beneficial long-term effects. Surgical intervention via tricuspid valve repair or replacement more definitively addresses valvular dysfunction, and according to current American College of Cardiology/American Heart Association guidelines is recommended in patients with severe TR undergoing left-sided valve surgery (class I), mild or greater TR combined with either tricuspid annular dilation or right-sided heart failure at the time of left-sided valve surgery (class IIa), and isolated severe TR with symptoms (class IIa) or with associated right ventricular dysfunction (class IIb).3 Despite these recommendations, however, less than 8000 tricuspid valve surgeries (TVS) are performed annually in the USA, of which only 500 are for isolated TR.1 This is primarily due to perceived surgical risk in patients with multiple comorbidities. Indeed, in-hospital mortality for patients receiving TVS has been estimated at approximately 8%–10%. Given the associated surgical risks, surgical intervention may be delayed in lieu …

View Full Text

Footnotes

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Valvular heart disease
    Amer N Kadri Vivek Menon Yasser M Sammour Rama D Gajulapalli Chandramohan Meenakshisundaram Leen Nusairat Divyanshu Mohananey Adrian V Hernandez Jose Navia Amar Krishnaswamy Brian Griffin Leonardo Rodriguez Serge C Harb Samir Kapadia